Key result
Non-peptide angiotensin type 1 receptor antagonists provide a gradual decrease in blood pressure comparable to conventional anti-hypertensives, with adverse effect frequencies better than placebo.
Why the study?
Do non-peptide angiotensin type 1 receptor antagonists safely reduce blood pressure in patients with hypertension?
Do non-peptide angiotensin type 1 receptor antagonists safely reduce blood pressure in patients with hypertension?
AT1 receptor antagonists are effective and exceptionally well-tolerated agents for the treatment of hypertension, with potential benefits for intermediate endpoints like micro-albuminuria and left ventricular hypertrophy.
No takes yet. Share an insight, caveat, or question.
May support ARB consideration in hypertension for efficacy and safety; leaves open need for outcome trials.
Birkenhäger et al. (1999) conducted a review in hypertension. Non-peptide angiotensin type 1 receptor antagonists vs. conventional anti-hypertensive drugs and placebo was evaluated. Non-peptide angiotensin type 1 receptor antagonists provide a gradual decrease in blood pressure comparable to conventional anti-hypertensives, with adverse effect frequencies better than placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: